MDAI — Spectral AI, Inc.

Summary of Spectral AI Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $3.8 million, down from $7.6 million in Q4 2024, reflecting a reduction in research direct labor and clinical trial costs as the company nears completion of the BARDA PBS contract.
• Gross Margin: 39.8% in Q4 2025, compared to 44.0% in Q4 2024, due to a lower percentage of reimbursed direct labor.
• General and Administrative Expenses: Decreased to $4.0 million from $4.5 million in Q4 2024.
• Net Income: $0.6 million ($0.02 per diluted share) in Q4 2025, a significant improvement from a net loss of $7.7 million ($-0.41 per diluted share) in Q4 2024.
• Full Year 2025 Revenue: $19.7 million, down from $29.6 million in 2024.
• Full Year Net Loss: $7.6 million ($-0.29 per diluted share), improved from a net loss of $15.3 million ($-0.85 per diluted share) in 2024.
• Cash Position: Increased to $15.4 million at year-end, up from $5.2 million in 2024.

2. Strategic Updates and Business Highlights

• DeepView System: Aimed at improving burn patient triage and treatment, with a de novo application submitted to the FDA in June 2025. The company is in active dialogue with the FDA and expects a response by Q2 2026.
• BARDA Partnership: Received an additional $31.7 million in funding to accelerate development and support features of the DeepView system. The contract allows for subsidized sales of up to 30 systems in U.S. burn centers post-FDA approval.
• International Expansion: Positive feedback from the UK, where the DeepView system has received UKCA authorization. Plans to expand authorization and initiate sales in late 2026.
• Handheld Device Development: Continued development under a Department of Defense contract, with a prototype expected by mid-2026.

3. Forward Guidance and Outlook

• 2026 Revenue Forecast: Approximately $18.5 million, not including significant contributions from DeepView system sales.
• Commercialization Strategy: Preparing for commercialization with plans to hire a Chief Commercial Officer and expand the sales team. Initial sales activities expected in late 2026, with a significant revenue boost anticipated in 2027 and 2028.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Notable decrease in both quarterly and annual revenue compared to previous periods, primarily due to the transition phase as the company approaches FDA approval.
• Dependency on FDA Approval: Future revenue and growth heavily reliant on timely FDA approval of the DeepView system.
• Market Adoption Risks: Uncertainty regarding how health systems will treat the deployment of the DeepView system (purchase vs. lease) could impact revenue recognition and overall business model.

5. Notable Q&A Insights

• Commercial Readiness: The company is actively preparing for commercialization, including hiring a Chief Commercial Officer and engaging consulting firms for strategic planning.
• BARDA Funding Utilization: The additional funding will accelerate product development and allow for expanded labeling and improved features of the DeepView system.
• International Opportunities: Plans to leverage FDA approvals for international sales, with a focus on the UK, Australia, and Gulf Cooperation Council nations.
• Training and Implementation: The company plans to expand its training force to ensure effective implementation of the DeepView system in burn centers, emphasizing the intuitive nature of the device.

Overall, Spectral AI is positioned for growth with a strong cash position and strategic partnerships, but faces challenges related to revenue decline and dependency on regulatory approvals.